Casein in milk as a functional ingredient for the prevention of sarcopenia

Completed

• Conditions: spiermetabolisme; Loss of muscle mass; sarcopenia

• Registration Number: NL-OMON40261
• Lead Sponsor: niversiteit Maastricht

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 29 April 2024

Recruitment & Eligibility

• Status: Completed
• Sex: Not specified
• Target Recruitment: 32

Inclusion Criteria

- Males
- Aged between 65-85 years
- Healthy, recreationally active (self-reported total of 2-4 hours of walking and/or light cycling (for transportation purposes) per week)
- BMI < 30 kg/m2
- No mobility limitations (i.e. able to perform all activities associated with daily living in a independent manner).

Exclusion Criteria

- Female
- Smoking
- Allergies to milk proteins (whey or casein)
- Arthritic conditions
- Over the counter antacids
- Diabetes mellitus type 1 and type 2 (fasting blood glucose above 6.1 mmol/L and and/or 2 hour OGTT glucose level higher than 7.8 mmol/L)
- A history of neuromuscular problems
- Individuals on any medications known to affect protein metabolism (i.e. corticosteroids, non-steroidal anti-inflammatories, or prescription strength acne medications).
- Participation in any structured regular exercise program
- Chronic use of gastric acid suppressing medication or anti-coagulants
- Unstable weight over the last three months
- Pathologies of the gastrointestinal tract

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>Primary endpoint: Muscle protein synthetic rate, expressed as fractional<br /><br>synthetic rate (FSR).</p><br>

Secondary Outcome Measures

Name	Time	Method
<p>Secondary endpoints: Rate of protein digestion and absorption and whole body<br /><br>protein balance</p><br>